The increased emphasis on R&D efforts by major companies is expected to fuel the global chronic myeloid leukaemia therapy market growth during the forecast period. Drugs for chronic myeloid leukaemia and its accompanying illnesses, such as blood malignancies, are in high demand. Market participants and non-profit groups in many nations are launching various activities and staging awareness campaigns in order to enhance chronic myeloid leukaemia medication production, which is projected to generate attractive prospects for chronic myeloid leukaemia medication producers and drive market expansion in the near future. The cost of therapy is an important element that determines treatment choices. As a result, the high cost of chronic myeloid leukaemia treatment medications is likely to stymie the worldwide chronic myeloid treatment market's expansion.
According to Coherent Makret Insights, the global Chronic Myeloid Leukemia Treatment Market is estimated to be valued at US$ 7,216.3 million in 2021, and is expected to exhibit a CAGR of 6.0% during the forecast period (2021-2028).
Key Leaders in the Chronic Myeloid Leukemia Treatment Industry:
1. Teva Pharmaceutical Industries Ltd
eva Pharmaceutical Industries is a global pharmaceutical company specializing in the development, production, and marketing of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients. Teva is among the top 20 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. The company was established on 1901, headquartered in Israel.
2. F. Hoffmann-La Roche Ltd.
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.
3. Novartis AG
The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. In January 2020, Novartis AG announced that it had completed acquisition of The Medicines Company, a pharmaceutical company. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol.
4. Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company was founded in 1887 and is headquartered in New York, New York.
5. Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide The Company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
6. Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company in Japan. The company markets its original products, such as the anti-prostatic cancer agent leuprolide acetate (marketed as Lupron Depot, Enantone, Prostap, and Leuplin), the anti-peptic ulcer agent lansoprazole (marketed as Prevacid, Ogast, Takepron, and other names), the anti-hypertensive agent candesartan cilexetil (marketed as Blopress, Kenzen, and Amias), and the anti-diabetic agent pioglitazone hydrochloride (marketed as Actos). Segments the company operates its business in two categories, Pharmaceutical business and other businesses. The company was founded in 1781.
7. Innovent Biologics, Inc.
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China. On August 2022, Innovent Biologics Inc IVBXF and Sanofi SA SNY have collaborated to develop and commercialize two Sanofi clinical-stage oncology assets - Phase 3 SAR408701 and Phase 2 SAR444245 combined with sintilimab.
8. Viatris Inc. (Mylan N.V.)
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
9. Celon Labs
Celon Laboratories Limited engages in developing, manufacturing, and marketing pharmaceutical products in the areas of oncology, anti-infective, and critical care markets. It produces un-coated and coated tablets, capsules, ampoules, vials, pre-filled syringes, and emulsion injections. The company also provides contract research manufacturing Services that include formulation development, lyophilization cycle development, QC testing, stability studies, and regulatory support services. It serves customers in the Asia Pacific, Africa, Latin America, CIS countries, and Eastern Europe. The company was incorporated in 2001 and is based in Hyderabad, India. The company is acquired by KELIX Bio.
*Definition- Chronic myeloid leukaemia (CML) is a kind of cancer that begins in bone marrow blood-forming cells. It mostly affects adults and only very rarely affects children. Chronic myeloid leukaemia generally appears beyond the age of 60. CML is a slow-growing malignancy that is treated with specific cancer medications such tyrosine kinase inhibitors, chemotherapy, or a bone marrow transplant.
